Deeplake Pharmaceuticals (Shandong) Co. Ltd. has patented oxazolo- or thiazolo-indole compounds acting as xanthine dehydrogenase/oxidase (XDH; XOR) and/or solute carrier family 22 member 12 (SLC22A12; URAT1) dual inhibitors. They are reported to be useful for the treatment of gout and hyperuricemia.